13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
86 檔
16.1%
The Q1 2025 SEC filing reveals that Perceptive Advisors LLC held a total portfolio value of $6.7B, covering 86 public equity positions.
In Q1 2025, Perceptive Advisors LLC adopted a defensive or profit-taking posture, trimming 28 positions and completely liquidating 27 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including VRNA, ACLXGBX, AM6) accounted for 16.1% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 14.72% | — | +2.68% | |
| 2 | ACLXGBX | Arcellx Inc | Stock-Other | 6.78% | — | -15.88% | |
| 3 | AM6 | Amicus Therapeutics Inc | Stock-Other | 6.19% | — | -11.47% | |
| 4 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.48% | -0.05% | +162.42% | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.77% | +0.28% | -30.76% | |
| 6 | NUVL | Nuvalent Inc-a | Stock-Other | 4.09% | -0.23% | -37.63% | |
| 7 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.80% | — | +0.37% | |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.66% | — | -38.96% | |
| 9 | MGTX | MeiraGTx Holdings plc | Stock-Other | 3.01% | +0.44% | — | |
| 10 | AORT | Artivion Inc | Stock-Other | 2.43% | -0.58% | — | |
| 11 | ALDX | Aldeyra Therapeutics Inc | Stock-Other | 1.88% | — | — | |
| 12 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.86% | -0.73% | -14.19% | |
| 13 | EOLS | Evolus Inc | Stock-Other | 1.75% | +0.16% | -19.76% | |
| 14 | IMVT | Immunovant Inc | Stock-Other | 1.72% | +0.01% | +32.95% | |
| 15 | SLDB | Solid Biosciences Inc | Stock-Other | 1.56% | +0.11% | +72.39% | |
| 16 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.54% | -4.08% | EXIT | |
| 17 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 1.50% | — | -42.51% | |
| 18 | ✓ | Immatics NV | Stock-Other | 1.49% | -0.42% | — | |
| 19 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.48% | +0.08% | +7.21% | |
| 20 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.46% | -0.06% | -46.53% | |
| 21 | INSM | Insmed Inc | Stock-Healthcare | 1.37% | — | +253.68% | |
| 22 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.32% | +2.03% | -10.15% | |
| 23 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.31% | -2.59% | -46.39% | |
| 24 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.24% | — | -11.80% | |
| 25 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.22% | — | — | |
| 26 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.13% | — | -33.12% | |
| 27 | ✓ | Merus N V | Stock-Other | 1.03% | — | +130.16% | |
| 28 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.98% | — | +16.24% | |
| 29 | ADMA | Adma Biologics Inc | Stock-Healthcare | 0.96% | -0.07% | +54.25% | |
| 30 | PCVX | Vaxcyte Inc | Stock-Other | 0.94% | — | -58.88% | |
| 31 | JANX | Janux Therapeutics Inc | Stock-Other | 0.93% | — | +18.65% | |
| 32 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.85% | -0.75% | +325.82% | |
| 33 | CELC | Celcuity Inc | Stock-Other | 0.84% | -1.95% | — | |
| 34 | ZYME | Zymeworks Inc | Stock-Other | 0.78% | -0.08% | -12.46% | |
| 35 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.71% | -0.46% | -35.65% | |
| 36 | OBIO | Orchestra Biomed Holdings In | Stock-Other | 0.69% | -0.09% | — | |
| 37 | BBNX | Beta Bionics Inc | Stock-Other | 0.69% | +0.04% | — | |
| 38 | PODD | Insulet CORP | Stock-Healthcare | 0.66% | — | -69.17% | |
| 39 | RGEN | Repligen CORP | Stock-Healthcare | 0.58% | -0.14% | — | |
| 40 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.57% | -0.54% | EXIT | |
| 41 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.54% | — | — | |
| 42 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.53% | -0.05% | — | |
| 43 | BSX | Boston Scientific CORP | Stock-Healthcare | 0.46% | +0.16% | NEW | |
| 44 | SION | Sionna Therapeutics Inc | Stock-Other | 0.46% | +0.08% | — | |
| 45 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.46% | -0.08% | EXIT | |
| 46 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.43% | — | -48.89% | |
| 47 | DXCM | Dexcom Inc | Stock-Healthcare | 0.43% | — | — | |
| 48 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.39% | -0.17% | EXIT | |
| 49 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.39% | — | — | |
| 50 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.38% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +6.5% | +2.68% | Add |
| 2 | EWTX | Edgewise Therapeutics Inc | +3.5% | +162.42% | Add |
| 3 | SLNOEUR | Soleno Therapeutics Inc | +1.9% | +0.37% | Add |
| 4 | INSM | Insmed Inc | +1.1% | +253.68% | Add |
| 5 | MGTX | MeiraGTx Holdings plc | +0.9% | — | Unchanged |
| 6 | SLDB | Solid Biosciences Inc | +0.8% | +72.39% | Add |
| 7 | BBNX | Beta Bionics Inc | +0.7% | NEW | New buy |
| 8 | ITCIEUR | Intra-cellular Therapies Inc | +0.7% | -38.96% | Trim |
| 9 | ✓ | Merus N V | +0.7% | +130.16% | Add |
| 10 | ALDX | Aldeyra Therapeutics Inc | +0.6% | — | Unchanged |
| 11 | RGEN | Repligen CORP | +0.6% | NEW | New buy |
| 12 | MDGL | Madrigal Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 13 | ADMA | Adma Biologics Inc | +0.5% | +54.25% | Add |
| 14 | PTGX | Protagonist Therapeutics Inc | +0.5% | -14.19% | Trim |
| 15 | DYN | Dyne Therapeutics Inc | +0.5% | +325.82% | Add |
| 16 | BSX | Boston Scientific CORP | +0.5% | NEW | New buy |
| 17 | SION | Sionna Therapeutics Inc | +0.5% | NEW | New buy |
| 18 | DXCM | Dexcom Inc | +0.4% | NEW | New buy |
| 19 | AQST | Aquestive Therapeutics Inc | +0.4% | NEW | New buy |
| 20 | OM | Outset Medical Inc | +0.3% | NEW | New buy |
| 21 | AMLX | Amylyx Pharmaceuticals Inc | +0.3% | +16.24% | Add |
| 22 | IRON | Disc Medicine Inc | +0.3% | NEW | New buy |
| 23 | IMVT | Immunovant Inc | +0.3% | +32.95% | Add |
| 24 | ADPT | Adaptive Biotechnologies | +0.2% | NEW | New buy |
| 25 | AORT | Artivion Inc | +0.2% | — | Unchanged |
| 26 | AKRO | Akero Therapeutics Inc | +0.2% | -33.12% | Trim |
| 27 | DCTH | Delcath Systems Inc | +0.2% | +824.84% | Add |
| 28 | EOLS | Evolus Inc | +0.2% | -19.76% | Trim |
| 29 | KMTS | Kestra Medical Technologies, Ltd. | +0.2% | NEW | New buy |
| 30 | OBIO | Orchestra Biomed Holdings In | +0.2% | — | Unchanged |
| 31 | APGE | Apogee Therapeutics Inc | +0.2% | +7.21% | Add |
| 32 | DRUG | Bright Minds Biosciences Inc | +0.2% | +10.16% | Add |
| 33 | IRD | Opus Genetics Inc | +0.2% | NEW | New buy |
| 34 | AVTX | Avalo Therapeutics Inc | +0.2% | NEW | New buy |
| 35 | ARGX | Argenx Se - Adr | +0.1% | -11.80% | Trim |
| 36 | INBX | Inhibrx Biosciences Inc | +0.1% | — | Unchanged |
| 37 | KALAEUR | Kala Bio Inc | +0.1% | NEW | New buy |
| 38 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 39 | ✓ | Helix Acquisition CORP Ii | 0% | -20.40% | Trim |
| 40 | CGEM | Cullinan Therapeutics Inc | 0% | NEW | New buy |
| 41 | NBIX | Neurocrine Biosciences Inc | 0% | — | Unchanged |
| 42 | ADGM | Adagio Medical Holdings Inc | — | — | Unchanged |
| 43 | SCPH | Scpharmaceuticals Inc | — | — | Unchanged |
| 44 | RVMDW | Revolution Medicines Inc-28 | — | — | Unchanged |
| 45 | APYX | Apyx Medical CORP | — | — | Unchanged |
| 46 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 47 | CELC | Celcuity Inc | 0% | — | Unchanged |
| 48 | OCUL | Ocular Therapeutix Inc | 0% | -15.09% | Trim |
| 49 | LYRAGBP | Lyra Therapeutics Inc | 0% | — | Unchanged |
| 50 | TRAW | Traws Pharma Inc | 0% | +156.94% | Add |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 86 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BBNX
市值: $19.5M
Top Position Liquidated / Trimmed
PRCT
前期市值: $23.4M
During Q1 2025, Perceptive Advisors LLC's top holdings by market value included VRNA (14.7%)、ACLXGBX (6.8%)、AM6 (6.2%). The largest single position, VRNA, represented 14.7% of total portfolio value.
In Q1 2025, Perceptive Advisors LLC made 85 total portfolio adjustments, initiating 15 new buys, adding to 15 positions, trimming 28 holdings, and fully liquidating 27 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.